Fostamatinib: First Global Approval

Abstract

Rigel Pharmaceuticals are developing the spleen tyrosine kinase (SYK) inhibitor fostamatinib (TAVALISSE™) as a treatment for immune thrombocytopenia (ITP), autoimmune haemolytic anaemia and IgA nephropathy. Based on positive results in the phase III FIT clinical trial program, the drug was recently approved in the US as a treatment for thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to a previous treatment. This article summarizes the milestones in the development of fostamatinib leading to this first approval.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Rigel Pharmaceuticals Inc. Fostamatinib (Tavalisse™): US prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209299lbl.pdf (2018). Accessed 9 May 2018.

  2. 2.

    Rigel Pharmaceuticals Inc. Rigel earns milestone payments from AstraZeneca [media release]. 29 Sept 2010. http://www.rigel.com.

  3. 3.

    Rigel Pharmaceuticals Inc. Rigel will resume responsibility for fostamatinib program [media release]. 4 Jun 2013. http://www.rigel.com.

  4. 4.

    Braselmann S, Taylor V, Zhao H, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006;319(3):998–1008.

    Article  PubMed  CAS  Google Scholar 

  5. 5.

    Podolanczuk A, Lazarus AH, Crow AR, et al. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood. 2009;113(14):3154–60.

    Article  PubMed  CAS  Google Scholar 

  6. 6.

    Martin P, Oliver S, Gillen M, et al. Pharmacokinetic properties of fostamatinib in patients with renal or hepatic impairment: results from 2 phase I clinical studies. Clin Ther. 2015;37(12):2823–36.

    Article  PubMed  CAS  Google Scholar 

  7. 7.

    Martin P, Gillen M, Millson D, et al. Effects of CYP3A4 inhibitors ketoconazole and verapamil and the CYP3A4 inducer rifampicin on the pharmacokinetic parameters of fostamatinib: results from in vitro and phase I clinical studies. Drugs R D. 2016;16(1):81–92.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. 8.

    Martin P, Gillen M, Ritter J, et al. Effects of fostamatinib on the pharmacokinetics of oral contraceptive, warfarin, and the statins rosuvastatin and simvastatin: results from phase I clinical studies. Drugs R D. 2016;16(1):93–107.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. 9.

    Martin P, Gillen M, Millson D, et al. Effects of fostamatinib on the pharmacokinetics of digoxin (a P-glycoprotein substrate): results from in vitro and phase I clinical studies. Clin Ther. 2015;37(12):2811–22.

    Article  PubMed  CAS  Google Scholar 

  10. 10.

    Martin P, Gillen M, Millson D, et al. Effects of fostamatinib on the pharmacokinetics of the CYP2C8 substrate pioglitazone: results from in vitro and phase 1 clinical studies. Clin Pharmacol Drug Dev. 2016;5(3):170–9.

    Article  PubMed  CAS  Google Scholar 

  11. 11.

    Flanagan T, Martin P, Gillen M, et al. Effects of ranitidine (antacid), food, and formulation on the pharmacokinetics of fostamatinib: results from five phase I clinical studies. Eur J Clin Pharmacol. 2017;73(2):185–95.

    Article  PubMed  CAS  Google Scholar 

  12. 12.

    Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018. https://doi.org/10.1002/ajh.25125.

    Article  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Kuter DJ, Arnold D, Agajanian R, et al. Fostamatinib, a spleen tyrosine kinase inhibitor, is active in the treatment of warm antibody autoimmune hemolytic anemia: results of the SOAR phase 2, multicenter, open-label study [poster]. In: 4th biennial summit of the thrombosis & hemostasis societies of North America. 2018.

  14. 14.

    Rigel Pharmaceuticals Inc. Rigel announces topline data from proof-of-concept phase 2 study of fostamatinib in IgA nephropathy [media release]. 3 Apr 2018. http://www.rigel.com.

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Anthony Markham.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. A. Markham, a contracted employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Markham, A. Fostamatinib: First Global Approval. Drugs 78, 959–963 (2018). https://doi.org/10.1007/s40265-018-0927-1

Download citation